A multi-institutional feasibility study of intra-arterial chemotherapy in children with retinoblastoma. A Children’s Oncology Group study (COG ARET12P1)

Chintagumpala M, Piao J, Gombos D, Chevez-Barrios P, Brock L, Dunkel IJ, Jubran R, Leahey AM, Kim J, O’Brien J, Shields CL, Rodriguez-Galindo C. A multi-institutional feasibility study of intra-arterial chemotherapy in children with retinoblastoma. A Children’s Oncology Group study (COG ARET12P1). Pediatr Blood Cancer. 2024 Jan;71(1):e30718. doi: 10.1002/pbc.30718. Epub 2023 Oct 10. PubMed PMID: 37817345; PubMed Central PMCID: PMC10842937.

Intra-arterial chemotherapy (IA) as a treatment to salvage the eye with advanced retinoblastoma is increasingly utilized based on successes reported by institutions around the world mainly through retrospective studies. The Children’s Oncology Group (COG) initiated study ARET12P1 in 2014 and was open to nine institutions. Eligible patients older than 6 months of age were enrolled. Feasibility of delivering 3 injections of melphalan into the ophthalmic artery every 28 days was assessed.